Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33532485 | 0.96 | CYP11B2 (0.41) | CYP11B2PDK2HDAC2NR1H2SCD5 | |
| SCHEMBL33530528 | 0.95 | PDK2 (0.41) | CYP11B2PDK2HDAC2NR1H2ESR2 | |
| SCHEMBL33530693 | 0.80 | PDK2 (0.44) | PDK2NR1H2ESR2GPR119 | |
| SCHEMBL33532834 | 0.78 | CYP11B2 (0.44) | CYP11B2HDAC2SCD5ACACBGPR119 | |
| SCHEMBL33531973 | 0.77 | CYP11B2 (0.43) | CYP11B2HDAC2SCD5GPR119HDAC1 | |
| SCHEMBL33531978 | 0.77 | CYP11B2 (0.43) | CYP11B2HDAC2SCD5GPR119RORC | |
| SCHEMBL33532144 | 0.75 | CYP11B2 (0.41) | CYP11B2PDK2GPR119 | |
| SCHEMBL485220 | 0.74 | CYP11B2 (0.53) | CYP11B2HDAC2SCD5GPR119RORC | |
| SCHEMBL485607 | 0.74 | HDAC2 (0.58) | CYP11B2HDAC2SCD5ACACBGPR119 | |
| SCHEMBL33533432 | 0.74 | CYP11B2 (0.40) | CYP11B2HDAC2SCD5GPR119RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | CYP11B2 4556/4885PDK2 4424/4885HDAC2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.